A cystine stone test looks for evidence of cystinuria, an inherited disorder that causes excessive cystine to spill into urine and form recurrent kidney stones. Diagnosis can involve stone analysis, 24-hour urine cystine, urine microscopy, a screening nitroprusside test, and sometimes genetic testing. The most direct evidence is a stone that contains cystine or a clearly elevated urinary cystine excretion. Cystinuria often causes stones at a younger age than common calcium stone disease and can lead to repeated procedures if prevention is not aggressive enough. A high urine cystine result does not stand alone: urine volume, pH, sodium intake, kidney function, and treatment use determine whether cystine remains dissolved or precipitates. Once the diagnosis is established, monitoring focuses on keeping urine dilute and alkaline enough to reduce cystine supersaturation and on checking for new stone growth over time.
- Cystinuria is a genetic cause of recurrent cystine stones, most often involving variants in the SLC3A1 or SLC7A9 genes.
- Urinary cystine above about 30 mg/day is abnormal, but people with classic cystinuria often excrete several hundred milligrams per day or more.
- Hexagonal cystine crystals strongly suggest cystinuria, while stone analysis can directly confirm cystine in a passed or removed stone.
- Genetic testing can confirm the molecular cause but is not required for every routine case when biochemical and stone findings are already clear.
- Treatment monitoring emphasizes urine volume and pH, commonly aiming for more than 3 L of urine per day in adults and urine alkalinization sufficient to keep cystine soluble.
Table of Contents
- What a Cystine Stone Test Is
- How to Interpret Urine Cystine Levels
- How Cystinuria Is Diagnosed
- SLC3A1, SLC7A9, and Genetic Risk
- What Positive and Abnormal Results Mean
- Monitoring and Treatment After Diagnosis
- Limitations, Family Testing, and Follow-Up
What a Cystine Stone Test Is
There is no single universal test called a “cystine stone test.” In practice, the term refers to a group of tests used to identify cystine stones and confirm cystinuria.
The most useful tests include:
- Stone composition analysis: confirms whether a passed or surgically removed stone contains cystine.
- 24-hour urine cystine: measures how much cystine is excreted over a full day.
- Urine microscopy: may show characteristic flat, colorless, hexagonal cystine crystals.
- Cyanide-nitroprusside screening: a qualitative urine test that can detect excess cystine.
- Genetic testing: looks for disease-causing variants in genes responsible for renal cystine transport.
- Cystine capacity: estimates whether treated urine is supersaturated or undersaturated with cystine.
A kidney stone analysis is particularly valuable because cystine has a distinctive chemical composition. Modern guidelines recommend reliable physical methods such as infrared spectroscopy or X-ray diffraction rather than relying only on older wet-chemical methods.
Cystinuria is uncommon compared with calcium stone disease, but it is clinically important because stones often begin early and recur frequently. Cystine stones account for only a small percentage of adult urinary stones, yet they represent a larger share of stones in children.
Cystine stones can grow quickly and may become large or form branching stone burdens. Repeated ureteroscopy, shock-wave treatment, or percutaneous procedures over a lifetime can add morbidity, so prevention is especially important. Cystine is also relatively hard compared with some other stone materials, and treatment response can differ by procedure and stone size. These practical consequences are why identifying the stone type early matters rather than treating every recurrent stone as an ordinary calcium stone.
The diagnosis can also explain findings that otherwise look disconnected. A teenager with several stones, a sibling with stones, persistently high urinary cystine, and hexagonal crystals has a coherent inherited disorder rather than several unrelated episodes of dehydration. That recognition changes counseling, family screening, and the intensity of long-term follow-up, while helping patients understand why lifelong prevention is necessary even during long symptom-free periods.
All confirmed cystine stone formers are generally considered high risk for recurrence. That means the diagnosis changes long-term follow-up even when the current stone has already passed or been removed.
How to Interpret Urine Cystine Levels
A 24-hour urine cystine measurement quantifies how much cystine the kidneys excrete. Current European guidance considers more than about 0.125 mmol/day, or 30 mg/day, abnormal. People with classic cystinuria usually excrete much more than that, often several hundred milligrams per day.
The absolute daily amount is only part of the risk. Stone formation depends on concentration and solubility. A person who excretes 700 mg of cystine into 4 L of urine has a different chemical environment from someone who excretes the same amount into 1.5 L.
Daily cystine excretion also changes with sodium intake and, to a lesser extent, protein and methionine intake. A high result on one collection may therefore reflect both the underlying transport defect and modifiable diet. For follow-up, clinicians often compare cystine with urine sodium, volume, pH, and creatinine rather than interpreting the number in isolation. A large apparent change in cystine without a plausible clinical reason should raise the question of collection error before major treatment changes are made.
Urine pH is equally important. Cystine is poorly soluble at ordinary acidic-to-neutral urine pH and becomes more soluble as urine becomes alkaline. This is why cystinuria treatment uses both high fluid intake and alkalinization.
Many clinical references discuss a cystine concentration around 250 mg/L as an approximate conventional solubility threshold, but the real relationship varies with pH, ionic strength, temperature, and treatment. A single concentration cutoff should therefore not be treated as a universal boundary between “safe” and “unsafe.”
For diagnosis, a urine cystine test can be very useful. During treatment with cystine-binding thiol drugs, however, conventional cystine assays may become harder to interpret because drug-cysteine complexes can interfere with measurement. In that setting, cystine capacity or specialized free-cystine methods may add useful information.
Collection accuracy matters. Missing urine can make daily cystine excretion look falsely low. Collecting longer than 24 hours can make it look falsely high. Creatinine, collection timing, and the patient’s usual expected urine volume can help identify an unreliable sample.
How Cystinuria Is Diagnosed
Cystinuria is diagnosed by combining the stone history with urine and stone findings. In a person with a confirmed cystine stone and clearly elevated urine cystine, the diagnosis is often straightforward.
Characteristic hexagonal crystals in fresh urine are highly suggestive because very few other urinary crystals have that shape. They may not appear in every sample, so their absence does not rule out cystinuria.
The cyanide-nitroprusside test is a screening option when cystinuria is suspected. European guidance reports sensitivity around 72% and specificity around 95%. False positives can occur, including with some medications and other metabolic disorders, so a positive screen should be confirmed with quantitative testing or stone analysis.
A 24-hour urine collection can confirm excessive cystine excretion and also measure volume, pH, sodium, creatinine, calcium, and citrate. These additional values matter because they guide treatment after diagnosis.
Stone analysis is especially useful when a patient has already passed or undergone removal of a stone. Cystine stones may have a yellowish, waxy appearance, but appearance alone is not reliable enough for diagnosis.
Imaging can suggest cystine but cannot confirm it. Cystine stones are visible on noncontrast CT and may be less radiopaque than many calcium stones on plain X-ray. Hounsfield units overlap across stone types, so CT density should not replace direct analysis when material is available.
A patient with recurrent stones in childhood or young adulthood, a strong family history, or repeated stones that do not fit common calcium or uric acid patterns should have a lower threshold for cystinuria evaluation.
SLC3A1, SLC7A9, and Genetic Risk
Cystinuria results from impaired transport of cystine and other dibasic amino acids in the kidney proximal tubule and intestine. The two main genes are SLC3A1 and SLC7A9, which encode parts of the amino acid transport system.
The traditional description of cystinuria as a simple autosomal recessive condition is incomplete. Many cases behave in a recessive pattern, but some SLC7A9 variants can produce increased cystine excretion in people with only one disease-causing variant. Modern classification therefore focuses more on genotype than older “type I, II, III” phenotypes.
The two proteins encoded by these genes work together as an amino acid transporter. When transport is impaired, cystine, ornithine, lysine, and arginine are lost in urine. Of those amino acids, cystine is the main stone problem because it is much less soluble. The others usually remain dissolved and do not form comparable stones. This explains why cystinuria is fundamentally an amino acid transport disorder even though its dominant clinical feature is nephrolithiasis.
Genetic testing can be useful when:
- the biochemical diagnosis is uncertain;
- the patient is very young or has an atypical presentation;
- family counseling is important;
- a sibling or relative needs risk assessment;
- the clinician suspects another inherited stone disorder;
- research or future gene-specific therapy is being considered.
Routine management does not always require genotyping. Current European guidance notes that genotype generally does not change the basic clinical treatment, because the main goals remain high urine volume, alkalinization, sodium restriction, and cystine-binding medication when needed.
Family members can still matter even without genetic testing. Because cystinuria is inherited and may be asymptomatic for years, siblings of an affected patient may be offered urine screening or further evaluation. Early identification can allow prevention before repeated obstructive stone events occur.
Genetic counseling is especially helpful for couples planning a family, families with several affected members, and patients trying to understand the inheritance pattern. The counselor can explain recurrence risk based on the specific variants found rather than using a one-size-fits-all percentage.
What Positive and Abnormal Results Mean
A positive cystine-related result has different meaning depending on the test.
| Test result | What it usually means |
|---|---|
| Cystine on stone analysis | Direct evidence that the patient forms cystine stones |
| Markedly high 24-hour urine cystine | Strong biochemical evidence of cystinuria |
| Hexagonal urine crystals | Strongly suggestive of cystinuria |
| Positive nitroprusside screen | Excess urinary cystine is possible; confirmatory testing is needed |
| Pathogenic SLC3A1 or SLC7A9 variants | Molecular confirmation of inherited cystinuria |
| Negative cystine capacity | Treated urine remains supersaturated and favors cystine precipitation |
A high cystine level does not mean a stone is currently obstructing the kidney. It indicates a biochemical tendency. Imaging is needed to locate stones and determine their size, number, and effect on urine flow.
Likewise, a low or improved cystine concentration during treatment does not guarantee that stone disease is controlled. Urine pH may still be too low, volume may drop overnight, or existing stones may continue to grow. This is why biochemical monitoring and imaging are paired.
A negative genetic test also does not always exclude cystinuria. Testing methods may not detect every pathogenic variant, and some clinically diagnosed patients have no clearly reportable variant with standard panels. Strong biochemical or stone evidence can therefore remain diagnostic even when genetics is unrevealing.
Cystinuria should also be distinguished from cystinosis, a different genetic disorder involving intracellular cystine accumulation and multi-organ disease. The names are similar, but the mechanisms, tests, and treatments are not the same.
Monitoring and Treatment After Diagnosis
The main treatment goal is to keep cystine below its crystallization threshold by diluting urine and increasing cystine solubility.
High fluid intake is the foundation. European guidance recommends enough intake to produce more than 3 L of urine per day in adults. This usually requires fluid across the entire day and often some attention to evening or overnight intake because urine becomes concentrated during long periods without drinking.
Alkalinization is the second major strategy. Potassium citrate is commonly used, with European guidance aiming for urine pH above 7.5. Other expert recommendations sometimes use targets above 7.0, depending on the patient and monitoring method. Excessive alkalinization can promote calcium phosphate precipitation, so the goal is controlled alkalinization rather than simply pushing pH as high as possible.
Reducing sodium intake can lower cystine excretion. European guidance advises avoiding more than about 2 g of sodium per day, which is roughly 5 g of salt. A urine sodium test can help show whether actual intake matches the plan.
If stones continue despite fluid, sodium reduction, and alkalinization, cystine-binding thiol drugs such as tiopronin or D-penicillamine may be used. These drugs form more soluble cysteine compounds and can lower cystine supersaturation. They require monitoring for adverse effects, including proteinuria and other drug-specific toxicities.
A cystine capacity test can be particularly useful after thiol therapy begins because it estimates whether the urine is still supersaturated even when standard cystine concentration becomes difficult to interpret.
Follow-up usually includes 24-hour urine testing, home urine pH monitoring, blood pressure, kidney function, medication safety tests, and periodic imaging. The exact interval is individualized based on stone activity and treatment stability.
Imaging frequency is chosen to balance early detection with radiation exposure. Ultrasound is often useful for surveillance, especially in children and younger adults, while low-dose noncontrast CT may be needed when ultrasound is uncertain or a precise stone burden is required. The best monitoring plan tracks both chemistry and anatomy: improved urine numbers are reassuring, but stable or shrinking stone burden provides the strongest evidence that prevention is working.
Limitations, Family Testing, and Follow-Up
Cystinuria testing has several limitations. Urinary cystine varies with diet, sodium intake, fluid intake, pH, collection completeness, and treatment. One apparently acceptable 24-hour sample does not prove that urine remains safe every day or overnight.
Stone analysis can also be misleading if only a tiny fragment is analyzed from a mixed or layered stone. Reliable methods and adequate sampling improve accuracy. If a result does not fit the clinical picture, repeat analysis of a new stone may be worthwhile.
Genetic results require careful interpretation. A variant of uncertain significance is not the same as a confirmed disease-causing variant, and testing cannot predict exactly how many stones a person will form.
Because cystinuria can damage kidney function through recurrent obstruction, infection, and procedures, long-term follow-up is important even when symptoms are absent. Imaging can detect silent stone growth before it causes renal colic.
Siblings and other close relatives may benefit from screening, particularly if they have urinary symptoms or a history of stones. Early testing is especially important in children from affected families because prevention can begin before a large stone burden develops.
Seek urgent care for flank pain with fever or chills, inability to urinate, persistent vomiting, severe uncontrolled pain, or symptoms in a person with a single functioning kidney. Cystinuria prevention is a long-term strategy; suspected infected obstruction is an emergency.
The most useful interpretation of a cystine stone test is therefore not simply “positive” or “negative.” It identifies a lifelong, high-recurrence stone disorder and opens the door to specific monitoring targets that can meaningfully reduce future stone growth and procedures. Consistent long-term follow-up is important even when symptoms are absent, because silent stones can enlarge between painful episodes and early biochemical changes may be easier to correct than a new obstructing stone.
References
- Cystinuria: Diagnosis, Medical and Surgical Management, and Emerging Therapies. A Narrative Review. 2026 (Review)
- Metabolic Evaluation and Recurrence Prevention – EAU Guidelines on Urolithiasis – Uroweb 2026 (Guideline)
- Cystinuria 2025 (Review)
- A Summary of Current Guidelines and Future Directions for Medical Management and Monitoring of Patients with Cystinuria. 2023 (Review)
- Pharmacological interventions for the management of cystinuria: a systematic review 2023 (Systematic Review)
- Cystinuria: an update on pathophysiology, genetics, and clinical management 2022 (Review)
Disclaimer
This article is for general education and does not replace medical or genetic evaluation. Cystine reference limits, pH targets, medication choices, and monitoring schedules vary by laboratory and individual health factors. People with suspected or confirmed cystinuria should work with a clinician experienced in recurrent or inherited kidney stone disease.
